These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor. Capurro V; Lanfranco M; Summa M; Porceddu PF; Ciampoli M; Margaroli N; Durando L; Garrone B; Ombrato R; Tongiani S; Reggiani A Biomed Pharmacother; 2020 Aug; 128():110249. PubMed ID: 32470749 [TBL] [Abstract][Full Text] [Related]
3. Amaryllidaceae alkaloids from Narcissus pseudonarcissus L. cv. Dutch Master as potential drugs in treatment of Alzheimer's disease. Hulcová D; Maříková J; Korábečný J; Hošťálková A; Jun D; Kuneš J; Chlebek J; Opletal L; De Simone A; Nováková L; Andrisano V; Růžička A; Cahlíková L Phytochemistry; 2019 Sep; 165():112055. PubMed ID: 31261031 [TBL] [Abstract][Full Text] [Related]
4. Discovery of new GSK-3β inhibitors through structure-based virtual screening. Dou X; Jiang L; Wang Y; Jin H; Liu Z; Zhang L Bioorg Med Chem Lett; 2018 Jan; 28(2):160-166. PubMed ID: 29208522 [TBL] [Abstract][Full Text] [Related]
5. Discovery of Selective, Substrate-Competitive, and Passive Membrane Permeable Glycogen Synthase Kinase-3β Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling of New C-Glycosylflavones. Liang Z; Li QX ACS Chem Neurosci; 2018 May; 9(5):1166-1183. PubMed ID: 29381861 [TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review. Xu M; Wang SL; Zhu L; Wu PY; Dai WB; Rakesh KP Eur J Med Chem; 2019 Feb; 164():448-470. PubMed ID: 30616053 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease. Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466 [TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3β inhibitors. Lozinskaya NA; Babkov DA; Zaryanova EV; Bezsonova EN; Efremov AM; Tsymlyakov MD; Anikina LV; Zakharyascheva OY; Borisov AV; Perfilova VN; Tyurenkov IN; Proskurnina MV; Spasov AA Bioorg Med Chem; 2019 May; 27(9):1804-1817. PubMed ID: 30902399 [TBL] [Abstract][Full Text] [Related]
9. Glycogen Synthase Kinase-3β as a Putative Therapeutic Target for Bipolar Disorder. Dandekar MP; Valvassori SS; Dal-Pont GC; Quevedo J Curr Drug Metab; 2018; 19(8):663-673. PubMed ID: 29283064 [TBL] [Abstract][Full Text] [Related]
10. Synthesis of Coumarin Derivatives as Versatile Scaffolds for GSK-3β Enzyme Inhibition. Francisco CS; Javarini CL; de S Barcelos I; Morais PAB; de Paula H; de S Borges W; Neto ÁC; Lacerda V Curr Top Med Chem; 2020; 20(2):153-160. PubMed ID: 31648640 [TBL] [Abstract][Full Text] [Related]
11. An Overview of Discovery of Thiazole Containing Heterocycles as Potent GSK-3β Inhibitors. Sharma D; Malhotra A; Bansal R Curr Drug Discov Technol; 2018; 15(3):229-235. PubMed ID: 29299988 [TBL] [Abstract][Full Text] [Related]
12. Derivatives of the β-Crinane Amaryllidaceae Alkaloid Haemanthamine as Multi-Target Directed Ligands for Alzheimer's Disease. Kohelová E; Peřinová R; Maafi N; Korábečný J; Hulcová D; Maříková J; Kučera T; Martínez González L; Hrabinova M; Vorčáková K; Nováková L; De Simone A; Havelek R; Cahlíková L Molecules; 2019 Apr; 24(7):. PubMed ID: 30987121 [TBL] [Abstract][Full Text] [Related]
13. Discovery and Evaluation of Enantiopure 9 Andreev S; Pantsar T; El-Gokha A; Ansideri F; Kudolo M; Anton DB; Sita G; Romasco J; Geibel C; Lämmerhofer M; Goettert MI; Tarozzi A; Laufer SA; Koch P Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33105671 [TBL] [Abstract][Full Text] [Related]
14. Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer. Walz A; Ugolkov A; Chandra S; Kozikowski A; Carneiro BA; O'Halloran TV; Giles FJ; Billadeau DD; Mazar AP Clin Cancer Res; 2017 Apr; 23(8):1891-1897. PubMed ID: 28053024 [TBL] [Abstract][Full Text] [Related]
15. The discovery of novel benzothiazinones as highly selective non-ATP competitive glycogen synthase kinase 3β inhibitors for the treatment of ovarian cancer. Gao Y; Ye DY; Zhou WC; Chu Y Eur J Med Chem; 2017 Jul; 135():370-381. PubMed ID: 28460311 [TBL] [Abstract][Full Text] [Related]
16. Therapeutic implications of glycogen synthase kinase-3β in Alzheimer's disease: a novel therapeutic target. Mandlik DS; Mandlik SK; S A Int J Neurosci; 2024 Jun; 134(6):603-619. PubMed ID: 36178363 [TBL] [Abstract][Full Text] [Related]
17. Marine Fungi as Producers of Benzocoumarins, a New Class of Inhibitors of Glycogen-Synthase-Kinase 3β. Wiese J; Imhoff JF; Gulder TA; Labes A; Schmaljohann R Mar Drugs; 2016 Oct; 14(11):. PubMed ID: 27801816 [TBL] [Abstract][Full Text] [Related]
18. Application of an ESI-QTOF method for the detailed characterization of GSK-3β inhibitors. De Simone A; Fiori J; Naldi M; D'Urzo A; Tumiatti V; Milelli A; Andrisano V J Pharm Biomed Anal; 2017 Sep; 144():159-166. PubMed ID: 28268049 [TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of (aza)indolyl maleimide-based covalent inhibitors of glycogen synthase kinase 3β. Yang Z; Liu H; Pan B; He F; Pan Z Org Biomol Chem; 2018 Jun; 16(22):4127-4140. PubMed ID: 29781013 [TBL] [Abstract][Full Text] [Related]
20. Role of glycogen synthase kinase-3β inhibitor AZD1080 in ovarian cancer. Chen S; Sun KX; Feng MX; Sang XB; Liu BL; Zhao Y Drug Des Devel Ther; 2016; 10():1225-32. PubMed ID: 27051274 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]